GH
Price
$162.98
Change
-$3.68 (-2.21%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
22.37B
14 days until earnings call
Intraday BUY SELL Signals
RPID
Price
$0.81
Change
-$0.01 (-1.22%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
40.94M
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GH vs RPID

GH vs RPID Comparison Chart in %
View a ticker or compare two or three
VS
GH vs. RPID commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a Hold and RPID is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GH with price predictions
Oct 21, 2026

GH in upward trend: price may jump up because it broke its lower Bollinger Band on October 08, 2026

GH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 39 cases where GH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 51 cases where GH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 241 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 175 of 210 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

GH moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GH crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-100.352) is normal, around the industry mean (64.450). P/E Ratio (-47.481) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for RPID with price predictions
Oct 21, 2026

RPID's RSI Indicator ascends from oversold territory

The RSI Oscillator for RPID moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 28 of the 32 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RPID just turned positive on September 23, 2026. Looking at past instances where RPID's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

Following a +1.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPID advanced for three days, in 175 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

RPID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for RPID entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.307) is normal, around the industry mean (2.923). P/E Ratio (-0.735) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (1.465) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. RPID’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
GH: Fundamental Ratings
GH
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
PROFIT vs RISK RATING
1..100
78
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
56
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GHRPID
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend about 1 month ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (GH: $166.66 vs. RPID: $0.82)
Brand notoriety: GH: Notable vs. RPID: Not notable
GH represents the Medical Specialties, while RPID is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: GH: 143% vs. RPID: 25%
Market capitalization -- GH: $21.87B vs. RPID: $40.18M
GH [@Medical Specialties] is valued at $21.87B. RPID’s [@Medical/Nursing Services] market capitalization is $40.18M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The average market capitalization across the [@Medical Specialties] industry is $20.94B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GH’s FA Score shows that 1 FA rating(s) are green while RPID’s FA Score has 1 green FA rating(s).

  • GH’s FA Score: 1 green, 4 red.
  • RPID’s FA Score: 1 green, 4 red.
According to our system of comparison, GH is a better buy in the long-term than RPID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GH’s TA Score shows that 4 TA indicator(s) are bullish while RPID’s TA Score has 4 bullish TA indicator(s).

  • GH’s TA Score: 4 bullish, 6 bearish.
  • RPID’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, RPID is a better buy in the short-term than GH.

Price Growth

GH (@Medical Specialties) experienced а +2.25% price change this week, while RPID (@Medical/Nursing Services) price change was -0.13% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.

Reported Earning Dates

GH is expected to report earnings on Nov 05, 2026.

RPID is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Medical Specialties (-3.15% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Medical/Nursing Services (-1.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
GH
Daily Signal:
Gain/Loss:
RPID
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

GH and

Correlation & Price change

A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GH
1D Price
Change %
GH100%
+2.50%
NTRA - GH
51%
Loosely correlated
+1.84%
ADPT - GH
47%
Loosely correlated
+3.73%
PSNL - GH
46%
Loosely correlated
-0.25%
CSTL - GH
43%
Loosely correlated
+3.68%
RGEN - GH
42%
Loosely correlated
+0.63%
More

RPID and

Correlation & Price change

A.I.dvisor tells us that RPID and ISRG have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RPID and ISRG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPID
1D Price
Change %
RPID100%
+5.77%
ISRG - RPID
30%
Poorly correlated
-2.26%
QDEL - RPID
28%
Poorly correlated
-0.91%
CDNA - RPID
27%
Poorly correlated
+2.23%
GH - RPID
27%
Poorly correlated
+2.50%
ALC - RPID
26%
Poorly correlated
-0.59%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNEX57.430.32
+0.56%
Stonex Group Inc
FSHP11.29N/A
N/A
Flag Ship Acquisition Corp
AMGN438.34-0.60
-0.14%
Amgen
SAFT103.94-0.19
-0.18%
Safety Insurance Group
GASS8.28-0.04
-0.48%
StealthGas